Erin Boh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Erin Boh has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Brittany Stumpf
Department of Dermatology, Tulane University School of Medicine, New Orleans, Louisiana
3 shared publications- Abby Jacobson
Bausch Health Companies Inc Bridgewater New Jersey USA
1 shared publication Alexandria Brown
Department of Dermatology, Tulane University School of Medicine, New Orleans, Louisiana
1 shared publicationAndrew Joselow
Tulane University School of Medicine
1 shared publication- Bradley Saylors
Department of Dermatology, Tulane University School of Medicine, New Orleans, Louisiana
1 shared publication Carole Bitar
Department of Dermatology, Tulane University, New Orleans, Louisiana
1 shared publication
Latest Publications
- Open Access
- 13 September 2024
- Published by Elsevier in JAAD Case Reports
- Vol. 53, 149-150
Response to Rodríguez-Cuadrado et al’s “Clinical, histopathologic, immunohistochemical, and electron microscopic findings in cutaneous monkeypox: A multicenter retrospective case series in Spain”
- 13 September 2024
- Published by Elsevier in JAAD Case Reports
- Vol. 53, 149-150
Open AccessResponse to Rodríguez-Cuadrado et al’s “Clinical, histopathologic, immunohistochemical, and electron microscopic findings in cutaneous monkeypox: A multicenter retrospective case series in Spain”
- Open Access
- 2 February 2023
- Published by Springer Nature in Dermatology and Therapy
- Vol. 13 (3) , 835-842
Healthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma
Introduction Cutaneous T-cell lymphoma (CTCL) is a rare, heterogeneous group of non-Hodgkin lymphomas characterized by various clinical, molecular, and histopathologic features of the skin. Variants of CTCL share many clinical features with common inflammatory skin diseases such as atopic dermatitis and psoriasis, making accurate and early diagnosis challenging in clinical settings. Inappropriate treatment or a delay in diagnosis can lead to increased morbidity and mortality. Here, we report findings from an online survey that investigated dermatology community practice, knowledge, and education surrounding CTCL. Methods An electronic survey of ten questions was developed and approved by physician experts in CTCL to assess experiences in diagnosing and treating CTCL among healthcare providers (HCPs). The survey was deployed to 10,600 US dermatology HCPs, including medical doctors (MDs), doctors of osteopathic medicine (DOs), nurse practitioners (NPs), and physician assistants (PAs) and excluding HCPs associated with CTCL centers of excellence. Results Among 44 HCPs who responded and were eligible for inclusion, 82% had diagnosed between one and ten CTCL cases in the last 5 years. Most respondents (91%) reported that they include CTCL in their differential diagnoses after patients do not respond to treatment of more common conditions. Patients with CTCL were frequently diagnosed with other inflammatory dermatoses—most commonly dermatitis and psoriasis—before a CTCL diagnosis, and many were treated with ineffective therapies for years. The most common length of time before a CTCL diagnosis was made was between 1 and 3 years, though 16% of HCPs reported that patients were treated for other diseases or skin conditions for ≥ 5 years. Two-thirds of HCPs agreed that further education surrounding CTCL is needed. Conclusions Given the infrequency of CTCL and its similar presentation to other common dermatologic conditions, increased education of CTCL is needed in the dermatology community to improve patient outcomes.
- 2 February 2023
- Published by Springer Nature in Dermatology and Therapy
- Vol. 13 (3) , 835-842
Open AccessHealthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma
Introduction Cutaneous T-cell lymphoma (CTCL) is a rare, heterogeneous group of non-Hodgkin lymphomas characterized by various clinical, molecular, and histopathologic features of the skin. Variants of CTCL share many clinical features with common inflammatory skin diseases such as atopic dermatitis and psoriasis, making accurate and early diagnosis challenging in clinical settings. Inappropriate treatment or a delay in diagnosis can lead to increased morbidity and mortality. Here, we report findings from an online survey that investigated dermatology community practice, knowledge, and education surrounding CTCL. Methods An electronic survey of ten questions was developed and approved by physician experts in CTCL to assess experiences in diagnosing and treating CTCL among healthcare providers (HCPs). The survey was deployed to 10,600 US dermatology HCPs, including medical doctors (MDs), doctors of osteopathic medicine (DOs), nurse practitioners (NPs), and physician assistants (PAs) and excluding HCPs associated with CTCL centers of excellence. Results Among 44 HCPs who responded and were eligible for inclusion, 82% had diagnosed between one and ten CTCL cases in the last 5 years. Most respondents (91%) reported that they include CTCL in their differential diagnoses after patients do not respond to treatment of more common conditions. Patients with CTCL were frequently diagnosed with other inflammatory dermatoses—most commonly dermatitis and psoriasis—before a CTCL diagnosis, and many were treated with ineffective therapies for years. The most common length of time before a CTCL diagnosis was made was between 1 and 3 years, though 16% of HCPs reported that patients were treated for other diseases or skin conditions for ≥ 5 years. Two-thirds of HCPs agreed that further education surrounding CTCL is needed. Conclusions Given the infrequency of CTCL and its similar presentation to other common dermatologic conditions, increased education of CTCL is needed in the dermatology community to improve patient outcomes.
- Open Access
- 1 December 2022
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 158 (12) , 1357-1366
Apremilast in Recalcitrant Cutaneous Dermatomyositis
Importance: Cutaneous disease in dermatomyositis has no standardized treatment approach and so presents a challenging task for patients and clinicians.Objective: To study the efficacy and safety of apremilast as an add-on therapy in patients with recalcitrant cutaneous dermatomyositis.Design, Setting, and Participants: This phase 2a, open-label, single-arm nonrandomized controlled trial was conducted at a single center from June 2018 to June 2021. Participants were 8 patients with recalcitrant cutaneous dermatomyositis, defined by a cutaneous disease activity severity index (CDASI) score greater than 5 despite treatment with steroids, steroid-sparing agents, or both. Data were analyzed from June 2018 to June 2021.Interventions: Apremilast 30 mg orally twice daily was added to ongoing treatment regimens.Main Outcomes and Measures: The primary outcome was the overall response rate (ORR) at 3 months. Key secondary outcomes were the safety and toxicity of apremilast and the durability of response at 6 months. The CDASI, muscle score, dermatology life quality index (DLQI), and depression assessments were performed at baseline and regularly until month 7. Skin biopsies were performed at baseline and 3 months after apremilast (defined as 3 months into active apremilast therapy) and tested for gene expression profiling and immunohistochemical stains. Adverse events were assessed using the Common Terminology Criteria for Adverse Events version 5.0.Results: Among 8 patients with recalcitrant cutaneous dermatomyositis (all women; mean [SD] age, 54 [15.9] years), a response was found at 3 months after apremilast among 7 patients (ORR, 87.5%). The mean (SD) decrease in CDASI was 12.9 (6.3) points at 3 months (P < .001). Apremilast was well tolerated, with no grade 3 or higher adverse events. Sequencing of RNA was performed on skin biopsies taken from 7 patients at baseline and at 3 months after therapy. Appropriate negative (ie, no primary antibody) and positive (ie, tonsil and spleen) controls were stained in parallel with each set of slides studied. Of 39 076 expressed genes, there were 195 whose expression changed 2-fold or more at P < .01 (123 downregulated and 72 upregulated genes). Gene set enrichment analysis identified 13 pathways in which apremilast was associated with downregulated expression, notably signal transducers and activators of transcription 1 (STAT1), STAT3, interleukin 4 (IL-4), IL-6, IL-12, IL-23, interferon γ (IFNγ), and tumor necrosis factor α (TNFα) pathways. In immunohistochemical staining, there was a mean (SD) decrease in phosphorylation levels STAT1 (22.3% [28.3%] positive cells) and STAT3 (13.4% [11.6%] positive cells) at the protein level, a downstream signaling pathway for the downregulated cytokines.Conclusions and Relevance: These findings suggest that apremilast was a safe and efficacious add-on treatment in recalcitrant dermatomyositis, with an overall response rate of 87.5% and associations with downregulation of multiple inflammatory pathways.Trial Registration: ClinicalTrials.gov Identifier: NCT03529955
- 1 December 2022
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 158 (12) , 1357-1366
Open AccessApremilast in Recalcitrant Cutaneous Dermatomyositis
Importance: Cutaneous disease in dermatomyositis has no standardized treatment approach and so presents a challenging task for patients and clinicians.Objective: To study the efficacy and safety of apremilast as an add-on therapy in patients with recalcitrant cutaneous dermatomyositis.Design, Setting, and Participants: This phase 2a, open-label, single-arm nonrandomized controlled trial was conducted at a single center from June 2018 to June 2021. Participants were 8 patients with recalcitrant cutaneous dermatomyositis, defined by a cutaneous disease activity severity index (CDASI) score greater than 5 despite treatment with steroids, steroid-sparing agents, or both. Data were analyzed from June 2018 to June 2021.Interventions: Apremilast 30 mg orally twice daily was added to ongoing treatment regimens.Main Outcomes and Measures: The primary outcome was the overall response rate (ORR) at 3 months. Key secondary outcomes were the safety and toxicity of apremilast and the durability of response at 6 months. The CDASI, muscle score, dermatology life quality index (DLQI), and depression assessments were performed at baseline and regularly until month 7. Skin biopsies were performed at baseline and 3 months after apremilast (defined as 3 months into active apremilast therapy) and tested for gene expression profiling and immunohistochemical stains. Adverse events were assessed using the Common Terminology Criteria for Adverse Events version 5.0.Results: Among 8 patients with recalcitrant cutaneous dermatomyositis (all women; mean [SD] age, 54 [15.9] years), a response was found at 3 months after apremilast among 7 patients (ORR, 87.5%). The mean (SD) decrease in CDASI was 12.9 (6.3) points at 3 months (P < .001). Apremilast was well tolerated, with no grade 3 or higher adverse events. Sequencing of RNA was performed on skin biopsies taken from 7 patients at baseline and at 3 months after therapy. Appropriate negative (ie, no primary antibody) and positive (ie, tonsil and spleen) controls were stained in parallel with each set of slides studied. Of 39 076 expressed genes, there were 195 whose expression changed 2-fold or more at P < .01 (123 downregulated and 72 upregulated genes). Gene set enrichment analysis identified 13 pathways in which apremilast was associated with downregulated expression, notably signal transducers and activators of transcription 1 (STAT1), STAT3, interleukin 4 (IL-4), IL-6, IL-12, IL-23, interferon γ (IFNγ), and tumor necrosis factor α (TNFα) pathways. In immunohistochemical staining, there was a mean (SD) decrease in phosphorylation levels STAT1 (22.3% [28.3%] positive cells) and STAT3 (13.4% [11.6%] positive cells) at the protein level, a downstream signaling pathway for the downregulated cytokines.Conclusions and Relevance: These findings suggest that apremilast was a safe and efficacious add-on treatment in recalcitrant dermatomyositis, with an overall response rate of 87.5% and associations with downregulation of multiple inflammatory pathways.Trial Registration: ClinicalTrials.gov Identifier: NCT03529955
- 27 November 2020
- Published by Springer Nature
- p. 103-118
Traditional Systemic Therapy I: Methotrexate and Cyclosporine
- 27 November 2020
- Published by Springer Nature
- p. 103-118
Traditional Systemic Therapy I: Methotrexate and Cyclosporine
- Open Access
- 1 February 2019
- Published by Elsevier in JAAD Case Reports
- Vol. 5 (2) , 191-194
Apremilast as a potential treatment for moderate to severe dermatomyositis: A retrospective study of 3 patients
- 1 February 2019
- Published by Elsevier in JAAD Case Reports
- Vol. 5 (2) , 191-194
Open AccessApremilast as a potential treatment for moderate to severe dermatomyositis: A retrospective study of 3 patients
- Open Access
- 1 March 2016
- Published by Elsevier in JAAD Case Reports
- Vol. 2 (2) , 95-97
Cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis in 2 travelers
- 1 March 2016
- Published by Elsevier in JAAD Case Reports
- Vol. 2 (2) , 95-97
Open AccessCutaneous leishmaniasis caused by Leishmania (Viannia) panamensis in 2 travelers
- 7 July 2014
- Published by Springer Nature
- p. 117-130
Traditional Systemic Therapy I: Methotrexate and Cyclosporine
- 7 July 2014
- Published by Springer Nature
- p. 117-130
Traditional Systemic Therapy I: Methotrexate and Cyclosporine
- 1 March 2004
- Published by Elsevier in Clinics in Dermatology
- Vol. 22 (2) , 125-128
Neonatal lupus erythematosus
- 1 March 2004
- Published by Elsevier in Clinics in Dermatology
- Vol. 22 (2) , 125-128
Neonatal lupus erythematosus
- 1 July 2002
- Published by Elsevier in Dermatologic Clinics
- Vol. 20 (3) , 533-546
Cutaneous manifestations of gastrointestinal diseases
- 1 July 2002
- Published by Elsevier in Dermatologic Clinics
- Vol. 20 (3) , 533-546
Cutaneous manifestations of gastrointestinal diseases